You are here

Leukemia Insights: Vol. 16, No. 1 Spring 2011

sandy craine's picture
Submitted by sandy craine on Wed, 27/04/2011 - 8:11pm

 

New Strategies for Chronic Myelogenous Leukemia

Despite the major advances in therapy with the successes of imatinib and second-generation tyrosine kinase inhibitors, there is room for improving the management of patients with chronic myelogenous leukemia. Presently, there are clinical trials addressing the different stages of  CML. Some of the available clinical trials are reviewed here.

 

New Strategies for Chronic Myelogenous Leukemia

Despite the major advances in therapy with the successes of imatinib and second-generation tyrosine kinase inhibitors, there is room for improving the management of patients with chronic myelogenous leukemia. Presently, there are clinical trials addressing the different stages of  CML. Some of the available clinical trials are reviewed here.

Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

sandy craine's picture
Submitted by sandy craine on Thu, 21/04/2011 - 6:15pm
Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy Hagop Kantarjian and Jorge Cortes MD Anderson Cancer Center, Houston, TX The phenomenal success of therapy with tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome (Ph) –positive chronic myeloid leukemia (CML) has drastically changed the prognosis of this disease. With imatinib mesylate, the estimated 7- to 10-year survival is 80% to 85%, 90% to 93% if only CML-related deaths are considered.1–5 Nilotinib and dasatinib are more potent second generation TKIs with activity in CML after imatinib failure.6–8

Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Hagop Kantarjian and Jorge Cortes
MD Anderson Cancer Center, Houston, TX

The phenomenal success of therapy with tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome (Ph) –positive chronic myeloid leukemia (CML) has drastically changed the prognosis of this disease. With imatinib mesylate, the estimated 7- to 10-year survival is 80% to 85%, 90% to 93% if only CML-related deaths are considered.1–5 Nilotinib and dasatinib are more potent second generation TKIs with activity in CML after imatinib failure.6–8

Blocking rogue gene could stop the spread of most cancers

sandy craine's picture
Submitted by sandy craine on Tue, 25/01/2011 - 11:45am

Published: 24/01/2011 12:27:29

Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.Published today by the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.

Published: 24/01/2011 12:27:29

Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.Published today by the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.

BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP

sandy craine's picture
Submitted by sandy craine on Sun, 16/01/2011 - 6:35pm

BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP

Posting Date: December 11, 2010

BELA: international, multicenter, randomized, open-label phase III study[1]

BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP

Posting Date: December 11, 2010

BELA: international, multicenter, randomized, open-label phase III study[1]

Seeking the causes of and solutions to imatinib resistance in CML

sandy craine's picture
Submitted by sandy craine on Sun, 16/01/2011 - 5:35pm

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

D Bixby and M Talpaz
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, US
read PDF here:

http://www.nature.com/leu/journal/v25/n1/pdf/leu2010238a.pdf

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

D Bixby and M Talpaz

Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, US

read PDF here:

http://www.nature.com/leu/journal/v25/n1/pdf/leu2010238a.pdf

Pages